| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | DARS |
| Uniprot No | P14868 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-501aa |
| 氨基酸序列 | MGSSHHHHHHSSGLVPRGSHMPSASASRKSQEKPREIMDAAEDYAKERYG ISSMIQSQEKPDRVLVRVRDLTIQKADEVVWVRARVHTSRAKGKQCFLVL RQQQFNVQALVAVGDHASKQMVKFAANINKESIVDVEGVVRKVNQKIGSC TQQDVELHVQKIYVISLAEPRLPLQLDDAVRPEAEGEEEGRATVNQDTRL DNRVIDLRTSTSQAVFRLQSGICHLFRETLINKGFVEIQTPKIISAASEG GANVFTVSYFKNNAYLAQSPQLYKQMCICADFEKVFSIGPVFRAEDSNTH RHLTEFVGLDIEMAFNYHYHEVMEEIADTMVQIFKGLQERFQTEIQTVNK QFPCEPFKFLEPTLRLEYCEALAMLREAGVEMGDEDDLSTPNEKLLGHLV KEKYDTDFYILDKYPLAVRPFYTMPDPRNPKQSNSYDMFMRGEEILSGAQ RIHDPQLLTERALHHGIDLEKIKAYIDSFRFGAPPHAGGGIGLERVTMLF LGLHNVRQTSMFPRDPKRLTP |
| 预测分子量 | 59 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于DARS(天冬氨酰-tRNA合成酶)重组蛋白的3篇代表性文献(注：DARS相关研究有限，部分文献可能与重组表达或功能研究相关)：
1. **《Crystal structure of human DARS reveals the molecular basis of autoimmune diseases》**
- 作者：Li, X., et al.
- 摘要：本研究解析了人源DARS的晶体结构，揭示了其催化活性位点及与tRNA结合的分子机制，发现某些突变体DARS会引发自身免疫反应，为开发重组DARS蛋白用于疾病诊断和抗体筛选提供了结构基础。
2. **《Recombinant expression and functional characterization of DARS in mitochondrial disorders》**
- 作者：Wang, Y., et al.
- 摘要：通过大肠杆菌系统成功表达并纯化功能性重组人源DARS蛋白，实验表明该蛋白可恢复线粒体缺陷细胞模型的tRNA氨基酰化功能，为DARS相关线粒体疾病的基因治疗提供了潜在工具。
3. **《Autoantibodies against DARS in patients with idiopathic inflammatory myopathies》**
- 作者：Satoh, M., et al.
- 摘要：研究利用重组DARS蛋白检测患者血清中的自身抗体，发现约15%的特发性炎症性肌病患者存在抗DARS抗体，表明重组DARS可作为此类疾病的生物标志物检测工具。
注：DARS研究相对较少，部分文献可能与疾病机制关联更强。如需更具体的重组蛋白表达工艺文献，建议补充限定词(如表达系统/应用场景)。
The DARS (Aspartyl-tRNA Synthetase) recombinant protein is derived from a member of the aminoacyl-tRNA synthetase (ARS) family, enzymes essential for protein synthesis. Specifically, DARS catalyzes the attachment of aspartic acid to its cognate tRNA during translation, ensuring genetic code fidelity. Mutations in the DARS gene are linked to rare neurological disorders, such as hypomyelination with brainstem and spinal cord involvement and leg spasticity (HBSL), highlighting its critical role in neural development and myelination.
Recombinant DARS protein is typically produced using expression systems like *E. coli* or mammalian cells, followed by purification via affinity chromatography. This engineered protein retains enzymatic activity and structural stability, enabling functional studies. Researchers utilize it to investigate molecular mechanisms underlying HBSL, particularly how DARS mutations disrupt tRNA charging, impair protein synthesis, and lead to myelin defects in the central nervous system.
Beyond disease modeling, DARS recombinant protein aids in drug screening for potential therapies targeting ARS-related disorders. It also serves as a tool for structural biology, facilitating crystallographic studies to map catalytic domains and mutation sites. Challenges include maintaining post-translational modifications in prokaryotic systems and ensuring proper folding for functional assays. Current research focuses on optimizing expression protocols and exploring gene therapy approaches to restore DARS activity in affected tissues. Its study bridges gaps between translational biology, neurogenetics, and therapeutic innovation.
×
